CCL21 cancer immunotherapy

Cancers

Volumn 6, Issue 2, 2014, Pages 1098-1110

  Lin, Yuan ^a   Sharma, Sherven ^a,b   John, Maie St ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Cancer immunotherapy; CCL21; Dendritic cell; Polymer; T cell

Indexed keywords

NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; DENDRITIC CELL; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MINOR HISTOCOMPATIBILITY COMPLEX; NANOPHARMACEUTICS; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84900516174     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6021098     Document Type: Review

References (58)

1. Cyster, J.G. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J. Exp. Med. 1999, 189, 447-450.
2. Gollmer, K.; Asperti-Boursin, F.; Tanaka, Y.; Okkenhaug, K.; Vanhaesebroeck, B.; Peterson, J.R.; Fukui, Y.; Donnadieu, E.; Stein, J.V. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 2009, 114, 580-588.
3. Friedman, R.S.; Jacobelli, J.; Krummel, M.F. Surface-bound chemokines capture and prime T cells for synapse formation. Nat. Immunol. 2006, 7, 1101-1108.
4. Flanagan, K.; Moroziewicz, D.; Kwak, H.; Hörig, H.; Kaufman, H.L. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell. Immunol. 2004, 231, 75-84.
5. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
6. Sharma, S.; Stolina, M.; Luo, J.; Strieter, R.M.; Burdick, M.; Zhu, L.X.; Batra, R.K.; Dubinett, S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent anti-tumor responses in vivo. J. Immunol. 2000, 164, 4558-4563.
7. Sharma, S.; Zhu, L.; Srivastava, M.K.; Harris-White, M.; Huang, M.; Lee, J.M.; Rosen, F.; Lee, G.; Wang, G.; Kickhoefe, V.; et al. CCL21 Chemokine Therapy for Lung Cancer. ITI 2013, 1, 10-15.
8. Sharma, S.; Yang, S.C.; Hillinger, S.; Zhu, L.X.; Huang, M.; Batra, R.K.; Lin, J.F.; Burdick, M.D.; Strieter, R.M.; Dubinett, S.M. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2003, 2, 22.
9. Yang, S.C.; Hillinger, S.; Riedl, K.; Zhang, L.; Zhu, L.; Huang, M.; Atianzar, K.; Kuo, B.Y.; Gardner, B.; Batra, R.K.; et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic anti-tumor responses and confers tumor immunity. Clin. Cancer Res. 2004, 10, 2891-2901.
10. Sharma, S.; Stolina, M.; Zhu, L.; Lin, Y.; Batra, R.; Huang, M.; Strieter, R.; Dubinett, S.M. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2001, 61, 6406-6412.
11. Kar, U.K.; Srivastava, M.K.; Andersson, A.; Baratelli, F.; Huang, M.; Kickhoefer, V.A.; Dubinett, S.M.; Rome, L.H.; Sharma, S. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 2011, 6, e0018758.
12. Nomura, T.; Haseqawa, H.; Kohno, M.; Sasaki, M.; Fujita, S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int. J. Cancer 2001, 91, 597-606.
13. Hillinger, S.; Yang, S.C.; Zhu, L.; Huang, M.; Duckett, R; Atianzar, K.; Batra, R.K.; Strieter. R.M.; Dubinett, S.M.; Sharma, S. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent anti-tumor responses in a lung cancer model. J. Immunol. 2003, 171, 6457-6465.
14. Shields, J.D.; Kourtis, I.; Tomei, A.A.; Roberts, J.M.; Swartz, M.A. Induction of lymphoid like stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328, 749-752.
15. Novak, L.; Igoucheva, O.; Cho, S.; Alexeev, V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol. Cancer Ther. 2007, 6, 1755-1764.
16. B16-F0, B16-F1, and B16-F10. Available online: http://atcc.custhelp.com/app/answers/detail/ a_id/1136/ (accessed on 22 March 2014).
17. Fidler, I.J.; Nicolson, G. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 1976, 57, 1199-1202.
18. Briles, E.B.; Kornfeld, S. Isolation and metastatic properties of detachment variants of B16 melanoma cells. J. Natl. Cancer Inst. 1978, 57, 1199-1202.
19. Liang, C.M.; Zhong, C.P.; Sun, R.X.; Liu, B.B.; Huang, C.; Qin, J.; Zhou, S.; Shan, J.; Liu, Y.K.; Ye, S.L. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J. Virol. 2007, 81, 9502-9511.
20. Yousefieh, N.; Hahto, S.M.; Stephens, A.L.; Ciavarra, R.P. Regulated expression of ccl21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic. model of prostate cancer. Cancer Microenviron. 2009, 2, 59-67.
21. Dieu-Nosjean, M.C.; Antoine, M.; Danel, C.; Heudes, D.; Wislez, M.; Poulot, V.; Rabbe, N.; Laurans, L.; Tartour, E.; de Chaisemartin, L.; et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26, 4410-4417.
22. Baratelli, F.; Takedatsu, H.; Hazra, S.; Peebles, K.; Luo, J.; Kurimoto, P.S.; Zeng, G.; Batra, R.K.; Sharma, S.; Dubinett, S.M. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J. Transl. Med. 2008, 6, 38.
23. Correale, P.; Rotundo; M.; Botta, C.; del Vecchio, M.T.; Ginanneschi, C.; Licchetta, A.; Conca, R.; Apollinari, S.; de Luca, F.; Tassone, P. Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma. Clin. Cancer Res. 2012, 18, 850-857.
24. Middel, P.; Brauneck, S.; Meyer, W.; Radzun, H.J. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 2010, 10, 578.
25. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991, 9, 271-296.
26. Heath, W.R.; Carbone, F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001, 19, 47-64.
27. Palucka, K.; Banchereau, J. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol. 2013, 25, 396-402.
28. Steinman, R.M. Dendritic cells and immune-based therapies. Exp. Hematol. 1996, 24, 859-862.
29. Bender, A.; Sapp, M.; Schuler, G.; Steinman, R.M.; Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 1996, 196, 121-135.
30. Tuyaerts, S.; Aerts, J.; Corthals, J.; Neyns, B.; Heirman, C.; Breckpot, K.; Thielemans, K.; Bonehill, A. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 2007, 56, 1513-1537.
31. Kiertscher, S.M.; Roth, M.D. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukoc. Biol. 1996, 59, 208-218.
32. Hovden, A.O.; Appel, S. The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA. Scand. J. Immunol. 2010, 72, 554.
33. Galluzzi, L.; Senovilla, L.; Vacchelli, E.; Eggermont, A.; Fridman, W.H.; Galon, J.; Sautès-Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012, 1, 1111-1134.
34. Yi, D.H.; Appel, S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand. J. Immunol. 2013, 78, 167-171.
35. Berk, E.; Muthuswamy, R.; Kalinski, P. Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine 2012, 30, 6216-6224.
36. Van Lint, S.; Heirman, C.; Thielemans, K.; Breckpot, K. mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum. Vaccin. Immunother. 2013, 9, 265-274.
37. Van Nuffel, A.M.; Benteyn, D.; Wilgenhof, S.; Pierret, L.; Corthals, J.; Heirman, C.; van der Bruggen, P.; Coulie, P.G.; Neyns, B.; Thielemans, K.; et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol. Ther. 2012, 20, 1063-1074.
38. Wilgenhof, S.; van Nuffel, A.M.; Benteyn, D.; Corthals, J.; Aerts, C.; Heirman, C.; van Riet, I.; Bonehill, A.; Thielemans, K.; Neyns, B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann. Oncol. 2013, 24, 2686-2693.
39. Akiyama, Y.; Watanabe, M.; Maruyama, K.; Ruscetti, F.W.; Wiltrout, R.H.; Yamaguchi, K. Enhancement of anti-tumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther. 2000, 7, 2113-2121.
40. Chen, Y.; Emtage, P.; Zhu, Q.; Foley, R.; Muller, W.; Hitt, M.; Gauldie, J.; Wan, Y. Induction of ErbB-2/neu-specific protective and therapeutic anti-tumor immunity using genetically modified dendritic cells: Enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther. 2001, 8, 316-323.
41. Furumoto, K.; Arii, S.; Yamasaki, S.; Mizumoto, M.; Mori, A.; Inoue, N.; Isobe, N.; Imamura, M. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic anti-tumor immune responses. Int. J. Cancer 2000, 87, 665-672.
42. Melero, I.; Duarte, M.; Ruiz, J.; Sangro, B.; Galofre, J.; Mazzolini, G.; Bustos, M.; Qian, C.; Prieto, J. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 1999, 6, 1779-1784.
43. Nishioka, Y.; Hirao, M.; Robbins, P.D.; Lotze, M.T.; Tahara, H. Induction of systemic and therapeutic anti-tumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999, 59, 4035-4041.
44. Miller, P.W.; Sharma, S.; Stolina, M.; Butterfield, L.H.; Luo, J.; Lin, Y.; Dohadwala, M.; Batra, R.K.; Wu, L.; Economou, J.S.; et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific anti-tumor immunity and achieves tumor eradication. Hum. Gene Ther. 2000, 11, 53-65.
45. Sharma, S.; Batra, R.; Yang, S.C.; Hillinger, S.; Zhu, L.; Atianzar, K.; Strieter, R.M.; Riedl, K.; Huang, M.; Dubinett, S.M. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum. Gene Ther. 2003, 14, 1511-1524.
46. Curiel-Lewandrowski, C.; Mahnke, K.; Labeur, M.; Roters, B.; Schmidt, W.; Granstein, R.D.; Luger T.A.; Schwarz, T.; Grabbe, S. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J. Immunol. 1999, 163, 174-183.
47. Kirk, C.J.; Hartigan-O'Connor, D.; Nickoloff, B.J.; Chamberlain, J.S.; Giedlin, M.; Aukerman, L.; Mule, J.J. T cell-dependent anti-tumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001, 61, 2062-2070.
48. Ribas, A.; Butterfield, L.H.; Glaspy, J.A.; Economou, J.S. Cancer immunotherapy using gene-modified dendritic cells. Curr. Gene Ther. 2002, 2, 57-78.
49. Riedl, K.; Baratelli, F.; Batra, R.K.; Yang, S.C.; Luo, J.; Escuadro, B.; Figlin, R.; Strieter, R.; Sharma, S.; Dubinett, S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol. Cancer 2003, 2, 35.
50. Yang, S.C.; Batra, R.K.; Hillinger, S.; Reckamp, K.L.; Strieter, R.M.; Dubinett, S.M.; Sharma, S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006, 66, 3205-3213.
51. Lee, J.M.; Garon, E.B.; Lee, M.; Baratelli, F.; Wang, G.; Abtin, F.; Suh, R.; Wallace, W.D.; Zeng, G.; Sharma, S.; et al. Phase I Trial of Trans.-thoracic Injection of CCL21 Gene Modified Dendritic Cells in Human Non-small Cell. Lung Carcinoma. Acad. Surg. Congr. 2014, ASC20140033.
52. Mulé, J.J. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Ann. N. Y. Acad. Sci. 2009, 1174, 33-40.
53. Huebsch, N.; Mooney, D.J. Inspiration and application in the evolution of biomaterials. Nature 2009, 462, 426-432.
54. Li, W.A.; Mooney, D.J. Materials based tumor immunotherapy vaccines. Curr. Opin. Immunol. 2013, 25, 238-245.
55. Hu, D.; Lau, O.; Wang, L.; Wang, G.; Schaue, D.; Zhu, L.; Huang, M.; Lin, Y.; Dennis, M.; Abemayor, E.; et al. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch. Otolaryngol. Head Neck Surg. 2012, 138, 412-417.
56. Lin, Y.; Luo, J.; Zhu, W.; Schaue, D.; Srivastava, M.; Elashoff, D.A.; Dubinett, S.M.; Sharma, S.; Wu, B.; St. John, M.A. A cytokine delivering polymer is effective in reducing tumor burden in an HNSCC murine model. Otolaryngol. Head Neck Surg. 2014, in press.
57. Ross, D.A.; Hundal, J.S.; Son, Y.H.; Ariyan, S.; Shin, J.; Lowlicht, R.; Sasaki, C.T. Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy. Laryngoscope 2004, 114, 1170-1176.
58. Ali, O.A.; Huebsch, N.; Cao, L.; Dranoff, G.; Mooney, D.J. Infection-mimicking materials to program dendritic cells in situ. Nat. Mater. 2009, 8, 151-158.